Address correspondence to: N. D. Pandita-Gunawardena. Fax: (+44)
|
|
- Nigel Armstrong
- 5 years ago
- Views:
Transcription
1 Age and Ageing 1999; 28: Amlodipine lowers blood pressure without affecting cerebral blood flow as measured by single photon emission computed tomography in elderly hypertensive subjects N. DAYA PANDITA-GUNAWARDENA, SUSAN E. M. CLARKE , British Geriatrics Society Department of Medicine for the Elderly, University Hospital Lewisham, Lewisham High Street, London SE13 6LH, UK 1 Department of Nuclear Medicine, Guy s Hospital, St Thomas Street, London, UK Address correspondence to: N. D. Pandita-Gunawardena. Fax: (+44) @compuserve.com Abstract Aim: to evaluate the effect of amlodipine on blood pressure and cerebral blood flow in elderly subjects with mild to moderate hypertension. Methods: a double-blind, parallel group study of 26 patients. After a 4-week placebo run-in period, amlodipine (5 10 mg) or matching placebo was given once daily for 8 weeks. Results: amlodipine significantly reduced blood pressure compared with baseline. Diastolic blood pressure was significantly reduced by amlodipine compared with placebo (P < 0.02 to P < 0.01). Ambulatory blood pressure monitoring showed that blood pressure control was sustained over the 24-h dosing interval. Relative regional cerebral blood flow, assessed using single photon emission computed tomography, was not significantly affected by amlodipine. Three placebo patients, but no amlodipine patients, withdrew because of adverse events. Conclusion: amlodipine was a well-tolerated and effective antihypertensive agent, and did not reduce regional cerebral blood flow in elderly hypertensive patients. Keywords: ambulatory blood pressure, amlodipine, cerebral blood flow, elderly, hypertension, single photon emission computed tomography Introduction Adequate control of high blood pressure (BP) is important to reduce cardiovascular morbidity and mortality [1, 2]. Twenty-four-hour control of BP may prevent excessive BP falls during the night, and minimize the BP rise that occurs early in the morning, when the risk of stroke, transient ischaemic attacks and myocardial infarction is greatest [3 5]. In normal subjects, a-adrenergic innervation, activation of the renin angiotensin system, and endothelial-derived relaxing and constricting factors contribute to autoregulation of cerebral blood flow [6]. Patients with long-standing hypertension frequently do not tolerate a sudden lowering of BP because of impaired cerebrovascular autoregulation, characterized by sluggish and incomplete autoregulatory responses [6, 7]. Pathogenic cerebrovascular changes such as atherosclerosis may render this impairment difficult to reverse, and antihypertensive treatment should not impair cerebral blood flow further. Calcium channel blockers induce beneficial peripheral haemodynamic effects in elderly patients [8 10] and do not appear to reduce cerebral perfusion [11 14]. Amlodipine is a calcium channel blocker which provides sustained antihypertensive activity over 24 h [15, 16], in elderly subjects as well as younger groups [17 20]. We have examined the effects of amlodipine on BP and regional cerebral blood flow, using single photon emission computed tomography (SPECT), in elderly subjects with mild to moderate hypertension. This is the first report of the use of SPECT to 451
2 N. D. Pandita-Gunawardena, S. E. M. Clarke measure cerebral blood flow in elderly hypertensive subjects. Patients and methods This was a double-blind, placebo-controlled, parallel group study, conducted according to the guidelines of the Declaration of Helsinki. The protocol was approved by the Lewisham and North Southwark committee on ethical practice. Written informed consent of all patients was obtained. Patients Patients of either sex aged 60 years had supine diastolic BP 95 mmhg, with upper limits of 105, 110 and 115 mmhg in patients aged 60 74, and 85 years, respectively. Exclusion criteria included: concurrent antihypertensive or vasodilator drugs; malignant hypertension; intolerance to calcium channel blockers; and stroke or myocardial infarction during the preceding 3 months. Treatment Patients were allocated to treatment groups by minimization [21] based on age, sex, body weight, smoking habit and supine diastolic BP. After a 4-week placebo run-in, patients received 5 mg amlodipine or placebo once daily in the morning for 8 weeks, doubled to 10 mg after 4 weeks if supine diastolic BP remained >90 mmhg (subject to toleration). Assessment of BP BP and heart rate were measured at each visit in the morning, approximately 24 h after the previous dose, with a random-zero sphygmomanometer, by the same examiner using the same arm. Measurements were made to the nearest 2 mmhg under quiet conditions after 5 min supine and 2 min standing. The mean of two measurements was recorded. Twenty-four-hour ambulatory BP and heart rate were recorded at baseline and after treatment, using a Spacelabs recorder. Recordings began before the daily dose of study treatment. Mean BP was calculated for each hour, and mean BP values for the daytime (start of recording until 2200 h), night-time ( h) and 24-h period were derived. Cerebral blood flow Cerebral blood flow was measured before and after treatment using SPECT [22]. Doses of MBq [ 99m technetium]-hexamethylpropylene amine oxime ([ 99m Tc]-HM-PAO; Ceretec, Amersham International) were injected intravenously and SPECT measurements were made min later under quiet conditions using a head scan g-camera. HM-PAO distribution was quantified in predefined regions of interest. Absolute regional uptake was calculated for the frontal, temporo-sylvian, parietal, occipital, basal ganglia and cerebellar [23, 24] areas. Absolute regional uptake was expressed as the photon count per pixel per MBq of injected [ 99m Tc]-HM-PAO (counts/mbq) and calculated with a decay correction factor based upon the half-life of 99m Tc. The regional to mean index (%) and regional to occipital index (%) were selected as regional perfusion indices: the latter has been shown to be the most sensitive index in detecting changes in regional cerebral blood flow [22]. Safety During each clinic visit, adverse events were elicited by the investigator using open questions such as how do you feel?, and were classified as mild, moderate or severe. Their relationship to study medication was noted. Statistical methods A linear-model repeated measures analysis of variance was used. All tests were two-tailed and the level of significance was taken as P < Statistical analyses were performed by an independent statistics house. It was estimated that, using an a level of 0.05, inclusion of 24 patients (12 per group) would show significant differences between groups in cerebral blood flow with a power of Results Of 26 patients enrolled, 23 completed the study. In the placebo group, two patients discontinued because of adverse events, one patient died of a myocardial infarction, three patients stopped taking study medication too early or too late, ambulatory BP measurements were started too late at the final visit for three patients, and cerebral blood flow was not measured for one patient. In the amlodipine group, ambulatory BP measurements and cerebral blood flow measurements were not recorded for two patients. These patients were excluded from the analysis. The treatment groups were well matched for demographic details (Table 1). A history of stroke was not recorded for any patient during the physical examination before the study. The mean maintenance daily dose of amlodipine was 7.3 mg, with seven patients remaining on 5 mg and six increasing the dose to 10 mg. The corresponding mean dose for placebo patients was 8.85 mg. Clinic BP and heart rate All mean BP values after 8 weeks of treatment were significantly lower than at baseline in the amlodipine group (P < ), whereas there was little change in 452
3 Amlodipine: effect on cerebral blood flow Table 1. Patient characteristics at baseline Amlodipine Placebo Parameter (n = 13) (n = 13)... Male/female 1/12 2/11 Age (years) Median Range Body weight (kg) Median Range Height (cm) Median Range Smoking habit Non-smoker 12 8 Smoker 1 3 Ex-smoker 0 2 Mean supine blood pressure (mmhg) 185/ /104 BP after placebo treatment (Table 2 and Figure 1). The difference between groups reached statistical significance for both supine and standing diastolic BP (P < 0.02 and P < 0.01, respectively). Supine and standing heart rate did not differ significantly between groups. Figure 1. Change in mean value of blood pressure following 8 weeks of treatment with amlodipine (B) or placebo (A). *P < 0.02; **P < 0.01 for the change with amlodipine versus the change with placebo. Ambulatory BP monitoring Amlodipine, but not placebo, induced clinically important BP reductions during the daytime, nighttime, and full 24-h periods (Figures 2 and 3). The effects of amlodipine were statistically significant relative to placebo for daytime systolic and diastolic BP, night-time systolic BP, and 24-h systolic and diastolic BP (Table 2 and Figure 3). Heart rate changes were slight and clinically unimportant. Table 2. Clinic and ambulatory blood pressures before and after 8 weeks of treatment with amlodipine or placebo Mean blood pressure (and SD), mmhg... Amlodipine Placebo Measurement Baseline 8 weeks Baseline 8 weeks... Clinic (n = 13) (n = 13) (n = 13) (n = 10) Supine Systolic 185 (11) 175 (19) 189 (15) 187 (23) Diastolic 104 (4) 93 (7) 104 (4) 99 (7) Standing Systolic 185 (11) 170 (18) 185 (18) 180 (190) Diastolic 104 (4) 90 (8) 101 (9) 99 (8) Ambulatory (n = 10) (n = 11) (n =7) (n =7) Daytime Systolic 177 (19) 156 (16) c 173 (20) 173 (19) Diastolic 97 (11) 84 (800 c 98 (11) 98 (11) Night-time Systolic 157 (22) 140 (20) a 162 (29) 165 (19) Diastolic 76 (16) 69 (12) 82 (15) 80 (6) 24-h Systolic 167 (170) 151 (160) b 169 (21) 170 (19) Diastolic 89 (12) 79 (90) b 92 (10) 92 (9) Values of clinic BP were determined approximately 24 h after the previous dose. All mean measurements of clinic BP after treatment in the amlodipine group were significantly lower than baseline measurements (P < ). There were no significant differences between baseline and after treatment measurements within the placebo group. Significance of changes in blood pressure measured by ambulatory monitoring: a P < 0.05; b P < 0.01; c P <
4 N. D. Pandita-Gunawardena, S. E. M. Clarke Figure 2. Mean hourly blood pressure measurements during 24 h ambulatory blood pressure monitoring in patients following 8 weeks of treatment with amlodipine ( ) or placebo (W). Cerebral blood flow The overall mean absolute regional uptake was not significantly different between the amlodipine and placebo groups, and relatively small, but statistically significant differences between the two groups were observed in only three of the 12 individual measurements (Table 3). Relative regional blood flow in the temporo-sylvian and frontal regions of the right and left hemisphere were not significantly changed after treatment relative to baseline or placebo (Table 4). Figure 3. Changes in mean values of ambulatory blood pressure following 8 weeks of treatment with amlodipine (B) or placebo (A). *P < 0.05 for the change with amlodipine versus the change with placebo. Adverse events No adverse events were reported in patients treated with amlodipine. Three placebo-treated patients experienced five adverse events which led to treatment withdrawal. A myocardial infarction in a patient receiving placebo was unrelated to treatment. Discussion This study confirms that amlodipine effectively reduces BP in elderly patients with mild to moderate Table 3. Absolute regional uptake of 99m technetium in selected brain regions before and after 8 weeks of treatment with placebo or amlodipine Mean absolute regional uptake (and SD), counts/mbq a... Amlodipine Placebo Baseline 8 weeks Baseline 8 weeks Region (n = 10) (n = 11) (n =6) (n =6) P value b... Frontal Right 355 (57) 337 (57) 330 (63) 351 (80) 0.04 Left 350 (56) 338 (57) 326 (61) 344 (79) 0.11 Temporo-sylvian Right 378 (47) 358 (54) 363 (92) 371 (92) 0.25 Left 384 (48) 361 (56) 363 (83) 370 (83) 0.21 Parietal Right 356 (49) 337 (52) 321 (55) 343 (76) 0.03 Left 353 (51) 332 (52) 323 (59) 348 (87) 0.03 Occipital Right 402 (64) 375 (68) 365 (67) 383 (86) 0.07 Left 406 (65) 388 (71) 370 (66) 379 (90) 0.23 Basal ganglia Right 403 (63) 384 (56) 375 (81) 386 (87) 0.21 Left 395 (67) 375 (60) 379 (81) 383 (87) 0.37 Cerebellum Right 445 (55) 430 (74) 415 (70) 435 (87) 0.12 Left 453 (63) 436 (75) 417 (71) 439 (89) 0.11 Mean overall value 390 (54) 371 (59) 363 (69) 377 (84) 0.11 a Photon counts per pixel per MBq of injected 99m Tc-HM-PAO. b For the difference between the change in counts following treatment for the amlodipine versus placebo groups. 454
5 Amlodipine: effect on cerebral blood flow Table 4. Relative regional cerebral blood flow in frontal and temporo-sylvian regions before and after 8 weeks of treatment with amlodipine and placebo, expressed as regional to mean (R/M) and regional to occipital (R/O) indices (%) for the right and left hemispheres Mean relative cerebral blood flow (and SD), %... Amlodipine Placebo Baseline 8 weeks Baseline 8 weeks Region Index Side (n = 10) (n = 11) (n =6) (n =6) P value a... Frontal R/M Right 91 (4) 91 (4) 91 (4) 93 (2) 0.28 Left 90 (4) 91 (4) 90 (4) 91 (2) 0.61 R/O Right 88 (7) 89 (7) 90 (5) 92 (2) 0.32 Left 87 (8) 89 (7) 89 (4) 90 (2) 0.74 Temporo-sylvian R/M Right 97 (3) 97 (4) 99 (7) 98 (4) 0.56 Left 99 (3) 98 (3) 100 (5) 98 (3) 0.76 R/O Right 94 (6) 94 (6) 98 (9) 97 (5) 0.53 Left 96 (8) 95 (4) 98 (7) 97 (4) 0.84 a For the difference between change following treatment for the amlodipine versus placebo groups. hypertension. BP was lowered throughout the 24-h dosing interval including the night and early morning hours. The antihypertensive activity of amlodipine is therefore consistent with previous studies in younger and older patients [17 19, 25]. Ambulatory BP measurement during normal activities [26] avoids the influence of white coat hypertension. In our study, amlodipine induced a significantly greater BP reductions than placebo during the daytime and night-time periods, and the magnitudes of BP lowering were of clinical importance. These results highlight the theoretical protection of the patients during the critical early-morning phase, when the risk of myocardial infarction and stroke is at its greatest. This pattern of response on ambulatory monitoring with amlodipine has not previously been described in elderly subjects. The confirmation of a reduction in BP after amlodipine treatment was essential to allow proper interpretation of the concomitant cerebral blood flow measurements made using SPECT. This method is well documented and reproducible, and keeps operatordependent steps to a minimum. Absolute regional uptake may be used to demonstrate changes in regional cerebral blood flow [22]. It does not require an internal standard. However, its value is limited by variations in the radiopharmaceutical dose administered and variations between subjects in tracer clearance, cardiac output and cerebral blood flow [23]. The regional to mean and regional to occipital indices are more reliable indicators of regional blood flow, since internal standards are used to compare tracer uptake in the brain region of interest with that of a reference area. However, the regional to mean index is marred by its inability to detect diffuse reductions of blood flow and by the difficulty of interpreting regional differences which interact with the mean and each other. The regional to occipital index appears to be the most reliable method: although studies in hypertensive patients are lacking, the occipital cortex in dementia has been shown to be relatively free of pathology [22], and the blood flow in the occipital cortex is unaffected by ageing [27]. The ability of the present study to detect small changes in cerebral perfusion was limited by the unexpectedly high rate of treatment withdrawals. However, despite the lowering of BP by amlodipine, the drug did not have a clinically important effect on cerebral blood flow, although small but statistically significant reductions in absolute regional uptake occurred in three out of 12 regions of interest. The lack of significant effect of amlodipine on relative indices of cerebral blood flow in the frontal area suggests that the reduction in frontal absolute regional uptake may have been a statistical artefact. Alternatively, as regional to occipital index and regional to mean index values for the parietal areas were not available, the possibility of a slight effect on blood flow in these areas cannot be excluded, and further investigation is required. Some calcium channel blockers display greater selectivity towards cerebral vessels than coronary or mesenteric vessels in vitro [27, 28]. Functionally, however, cerebrovascular blood flow may not be adversely affected by calcium channel blockers so long as the cerebral autoregulatory capacity is maintained. Previous clinical studies with dihydropyridine calcium channel blockers in hypertensive [11, 12] or normotensive [13] patients have not demonstrated reductions in cerebral blood flow. The results of 455
6 N. D. Pandita-Gunawardena, S. E. M. Clarke our study are therefore in agreement with previous clinical evaluations of the effects of calcium channel blockers. None of the amlodipine-treated patients experienced adverse events and all completed the 8-week treatment period. The good safety profile of amlodipine in the elderly patients of this study is in agreement with other amlodipine studies that have found an overall low incidence of adverse events and few differences between younger and older hypertensive patients [17]. In conclusion, this study provides further evidence that amlodipine, 5 10 mg once daily, reduces BP and is well tolerated in elderly hypertensive patients. The BP lowering activity was sustained for the full 24-h period between amlodipine doses and protected patients against the early-morning rise in BP that commonly occurs in untreated patients. Relative indices of cerebral blood flow in these patients were not reduced during amlodipine administration. Key points Once-daily amlodipine reduces blood pressure in elderly hypertensive patients. The antihypertensive effect was maintained throughout the 24-h dosing interval. Relative indices of cerebral blood flow were not significantly affected by amlodipine. Amlodipine was well tolerated in this elderly population. Acknowledgement This study was supported by a grant from Pfizer Ltd. References 1. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338: MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood pressure. Lancet 1978; 1: Sirgo MA, Mills RJ, De Quattro V. Effects of antihypertensive agents on circadian blood pressure and heart rate patterns. Arch Intern Med 1988; 148: Parati G, Pomidossi G, Alini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target organ damage in hypertension. J Hypertens 1987; 5: Strandgaard S, Paulson OB. Regulation of cerebral blood flow in health and disease. J Cardiovasc Pharmacol 1992; 19: S Wollner L, McCarthy ST, Soper NDW, Macy DJ. Failure of cerebral autoregulation in the elderly. Br Med J 1979: Forette F, Bert P, Rigaud AS. Are calcium antagonists the best option in elderly hypertensives? J Hypertens 1994; 12 (suppl.): S Bühler FR. Age and cardiovascular response adaptation: determinants of an hypertensive treatment concept primarily based on betablockers and calcium entry blockers. Hypertension 1983; 5 (suppl. 3): Douglas Smith C, McKendry RJR. Controlled trial of nifedipine in the treatment of Raynaud s phenomenon. Lancet 1982; II: Pandita-Gunawardena ND, Dorrance DE, Macdonald G. Efficacy of nitrendipine in the treatment of elderly hypertensive subjects, and its effect on cerebral blood flow. J Cardiovasc Pharmacol 1989; 14 (suppl. 10): S Thulin T, Fagher B, Grabowski M, Ryding E, Elmqvist J, Johansson BB. Cerebral blood flow in patients with severe hypertension, and acute and chronic effects of felodipine. J Hypertens 1993; 11: Kawaguchi M, Furuya H, Kurehara K, Yamada M. Effects of nicardipine on cerebral vascular responses to hypocapnia and blood flow velocity in the middle cerebral artery. Stroke 1991; 22: Bertel O. Nifedipine in hypertensive emergencies. Br Med J 1983; 286: Abernethy DR, Gutlowska J, Winterbottom LM. Effects of amlodipine: a long acting dihydropyridine calcium antagonist in ageing hypertension: pharmacodynamics in relation to disposition. Clin Pharmacol Ther 1990; 48: Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol 1986; 664: Cross BW, Kirby MG, Miller S, Shah SH, Sheldon DM, Sweeney MT. A multicentre study of the safety and efficacy of amlodipine in mild to moderate hypertension. Br J Clin Pract 1993; 47: Vandewoude MFJ, Lambert M, Vryens R. Open evaluation of amlodipine in the monotherapeutic treatment of systolic hypertension in the elderly. J Cardiovasc Pharmacol 1991; 17: S Varrone J and the Investigators of Study AML-NY The efficacy and safety of amlodipine in the treatment of mild and moderate essential hypertension in general practice. J Cardiovasc Pharmacol 1991; 17 (suppl. 1): S Osterloh I. The safety of amlodipine. Am Heart J 1989; 118: Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall, 1991; Goulding P, Burjan A, Smith R et al. Semi-automatic quantification of regional cerebral perfusion in primary degenerative dementia using 99m technetium-hexamethylpropylene amine oxime and single photon emission tomography. Eur J Nucl Med 1990; 17: Wai Yin Ho. Regional Cerebral Blood Flow in Elderly Hypertensive Patients Before and After Treatment with Amlodipine. MSc Thesis. London: University of London, Frick MH, McGibney D, Tyler HM. A dose response study of amlodipine in mild to moderate hypertension. J Intern Med 1989; 225: Burris JF, Allenby KS, Mroczek WJ. The effect of amlodipine on ambulatory blood pressure in hypertensive patients. Am J Cardiol 1994; 73: 39A 43A. 456
7 Amlodipine: effect on cerebral blood flow 26. Høegholm A, Kristensen KS, Madsen NH, Svendsen TL. White coat hypertension diagnosed by 24-h ambulatory monitoring. Examination of 159 newly diagnosed hypertensive patients. Am J Hypertens 1992; 5(2): Shaw TG, Mortel KF, Meyer JS, Rodgers RL, Hardenberg J, Cutaia MM. Cerebral blood flow changes in benign aging and cerebrovascular disease. Neurology 1983; 34: Marin J. Vascular effects of calcium antagonists. Uses in some cerebrovascular disorders. Gen Pharmacol 1988; 19: Shimitu K, Ohta T, Toda N. Evidence for greater susceptibility of isolated dog cerebral arteries to Ca antagonists than peripheral arteries. Stroke 1980; 11: Received 23 April 1997; accepted in revised form 28 October
The problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationBRIEF COMMUNICATIONS. KEY WORDS: Ambulatory blood pressure monitoring, placebo effect, antihypertensive drug trials.
AJH 1995; 8:311-315 BRIEF COMMUNICATIONS Lack of Placebo Effect on Ambulatory Blood Pressure Giuseppe Mancia, Stefano Omboni, Gianfranco Parati, Antonella Ravogli, Alessandra Villani, and Alberto Zanchetti
More informationThe hypertensive effects of the renin-angiotensin
Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point
More informationShould beta blockers remain first-line drugs for hypertension?
1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,
More informationCalculation of Trough-to-Peak Ratio in the Research Unit Setting
A]H 1996; 9:71S-75S Calculation of Trough-to-Peak Ratio in the Research Unit Setting Advantages and Disadvantages Henry L. Elliott and Peter A. Meredith The trough-to-peak ratio for the response to an
More informationEffects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris
Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments
More informationANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION*
Progress in Clinical Medicine 1 ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Keishi ABE** Asian Med. J. 44(2): 83 90, 2001 Abstract: J-MUBA was a large-scale clinical
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationantagonist, amlodipine
Br. J. clin. Pharmac. (1989), 27, 359-365 24 h blood pressure control with the once daily calcium antagonist, amlodipine M.. HBR, G. BRGDN,. AL-KHAWAJA &. B. RAFTRY The Cardiology Department and the Division
More informationHow well do office and exercise blood pressures predict sustained hypertension? A Dundee Step Test Study
(2000) 14, 429 433 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE How well do office and exercise blood pressures predict sustained hypertension?
More information& Wilkins. a Division of Cardiology, Schulich Heart Centre, b Institute for Clinical and
Original article 333 Optimum frequency of office blood pressure measurement using an automated sphygmomanometer Martin G. Myers a, Miguel Valdivieso a and Alexander Kiss b,c Objective To determine the
More informationRandomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
More informationVerapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design
Br J Clin Pharmacol 1998; 45: 491 495 Verapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design Juergen Scholze, 1 Peter Zilles 2 & Daniele Compagnone 2 on
More informationOverview of the outcome trials in older patients with isolated systolic hypertension
Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated
More informationHypertension. Penny Mosley MRPharmS
Hypertension Penny Mosley MRPharmS Outline of presentation Introduction to hypertension Physiological control of arterial blood pressure What determines our bp? What determines the heart rate? What determines
More informationPharmacodynarnic modeling of the antihypertensive response to amlodipine
Pharmacodynarnic modeling of the antihypertensive response to amlodipine The distinctive pharmacokinetic characteristics of amlodipine, particularly the long half-life, are presumed to translate directly
More informationIJRPC 2011, 1(3) Patel et al. ISSN: INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article EVALUATION OF COMPLIANCE AND BLOOD PRESSURE REDUCTION IN PATIENTS TREATED WITH AMLODIPINE
More information47 Hypertension in Elderly
47 Hypertension in Elderly YOU DO NOT HEAL OLD AGE; YOU PROTECT IT; YOU PROMOTE IT; YOU EXTEND IT Sir James Sterling Ross Abstract: The prevalence of hypertension rises with age and the complications secondary
More informationLarge therapeutic studies in elderly patients with hypertension
(2002) 16 (Suppl 1), S38 S43 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Large therapeutic studies in elderly patients with hypertension Centro Clinico Profesional
More informationDRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU
Original Article DRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU V.Gowri 1, K.Punnagai, K.Vijaybabu 3, Dr.Darling Chellathai 4 1 Assistant Professor
More informationfunction in patients with ischaemic heart disease
Br. J. clin. Pharmac. (1986), 22, 319S-324S Calcium antagonist treatment and its effects on left ventricular function in patients with ischaemic heart disease E. A. RODRIGUES, I. M. AL-KHAWAJA, A. LAHIRI
More informationCandesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients
1/5 This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
More informationAntihypertensive efficacy of olmesartan compared with other antihypertensive drugs
(2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal
More informationMorning Hypertension: A Pitfall of Current Hypertensive Management
Review Article Hypertension: A Pitfall of Current Hypertensive Management JMAJ 48(5): 234 240, 2005 Kazuomi Kario* 1 Abstract has recently attracted more attention because of the close relation between
More informationPrognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice
(2005) 19, 801 807 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured in the office, at home and
More informationIncidental Findings; Management of patients presenting with high BP. Phil Swales
Incidental Findings; Management of patients presenting with high BP Phil Swales Consultant Physician Acute & General Medicine University Hospitals of Leicester NHS Trust Objectives The approach to an incidental
More informationThe Evolution To Treatment Of Hypertension With Advanced Formulation
The Evolution To Treatment Of Hypertension With Advanced Formulation Dr. Donald Ang MBChB (UK) FRCP (Edin) MD (UK) CCST Cardiology (UK) FESC (Europe) Consultant Cardiologist Island Hospital Penang High
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationDrug treatments in hypertension outcome studies
The Second Australian National Blood Pressure Study Page 1 of 6 Background Outcome of treatment of hypertension Over the past 25 years studies of the drug treatment of mild-moderate hypertension have demonstrated
More informationDr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION.
Dr Diana R Holdright MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION www.drholdright.co.uk Blood pressure is the pressure exerted on the walls of the arteries when the heart pumps;
More informationBlood Pressure Variability and Its Management in Hypertensive Patients
Korean J Fam Med. 2012;33:330-335 http://dx.doi.org/10.4082/kjfm.2012.33.6.330 Blood Pressure Variability and Its Management in Hypertensive Patients Review Hee-Jeong Choi* Department of Family Medicine,
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationSponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title
Sponsor Novartis Generic Drug Name Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title A randomized, double-blind, multi-center, active-controlled, parallel
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationHypertension is a common disease in our
AJH 2000;13:1161 1167 Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on or Trefor O. Morgan, Adrianne Anderson, and Denise Bertram Arthritis and
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationEFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION
EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION Khemchandani D. 1 and * Arif A. Faruqui 2 1 Bairagarh,
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationValue of cardiac rehabilitation Prof. Dr. L Vanhees
Session: At the interface of hypertension and coronary heart disease haemodynamics, heart and hypertension Value of cardiac rehabilitation Prof. Dr. L Vanhees ESC Stockholm August 2010 Introduction There
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationESSENTIAL HYPERTENSION
E S S E N T I A L H Y P E R T E N S I O N Elevated blood pressure is one of the most important causes of cardiovascular disease. J A Ker MB ChB, MMed, MD Professor and Deputy Dean Faculty of Health Sciences
More informationTime of day for exercise on blood pressure reduction in dipping and nondipping hypertension
(2005) 19, 597 605 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE on blood pressure reduction in dipping and nondipping hypertension S Park,
More informationManaging Hypertension in the Perioperative Arena
Managing Hypertension in the Perioperative Arena Optimizing Perioperative Management Strategies for Hypertension in the Cardiac Surgical Patient Objectives: Treatment of hypertensive emergencies. ALBERT
More information...SELECTED ABSTRACTS...
The following abstracts, from peer-reviewed journals containing literature on vascular compliance and hypertension, were selected for their relevance to this conference and to a managed care perspective.
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationThe magnitude and duration of ambulatory blood pressure reduction following acute exercise
Journal of Human Hypertension (1999) 13, 361 366 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE The magnitude and duration of ambulatory
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
Anand IS,, 2014; Volume 3(3): 178-187 INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE EFFECT OF NEBIVOLOL AND METOPROLOL ON PLATELET ACTIVATION IN HYPERTENSIVE PATIENTS ANAND IS, PATEL
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationAmlodipine plus Lisinopril Tablets AMLOPRES-L
Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationfelodipine extended release or nifedipine retard
Br. J. clin. Pharmac. (1990), 30, 871-878 Control of blood pressure in hypertensive patients with felodipine extended release or nifedipine retard W. A. LITTLER Felodipine United Kingdom Hospital Study
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationHypotensive susceptibility and antihypertensive drugs Diana Solari Santa Margherita Ligure, 7 aprile 2016
Hypotensive susceptibility and antihypertensive drugs Diana Solari Santa Margherita Ligure, 7 aprile 2016 Arrhythmologic Center, Department of Cardiology, Lavagna SYNCOPE AND ANTIHYPERTENSIVE DRUGS Many
More informationEffects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease
European Heart Journal (2003) 24, 475 484 Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease PROGRESS Collaborative Group 1*
More informationAGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK. Michael Smolensky, Ph.D. The University of Texas Austin & Houston
AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK Michael Smolensky, Ph.D. The University of Texas Austin & Houston Disclosures Partner: Circadian Ambulatory Diagnostics Consultant: Spot On Sciences
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationThe role of statins in patients with arterial hypertension
Invited review The role of statins in patients with arterial hypertension Trygve B. Tjugen 1, Sigrun Halvorsen 1, Reidar Bjørnerheim 1, Sverre E. Kjeldsen 1, 2 1University of Oslo, Department of Cardiology,
More informationLowering blood pressure in 2003
UPDATE CLINICAL UPDATE Lowering blood pressure in 2003 John P Chalmers and Leonard F Arnolda Institute for International Health, University of Sydney, Sydney, NSW. John P Chalmers, MD, FRACP, Professor
More informationBlood Pressure Management in Acute Ischemic Stroke
Blood Pressure Management in Acute Ischemic Stroke Kimberly Clark, PharmD, BCCCP Clinical Pharmacy Specialist Critical Care, Greenville Health System Adjunct Assistant Professor, South Carolina College
More informationBaroreflex sensitivity and the blood pressure response to -blockade
Journal of Human Hypertension (1999) 13, 185 190 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Baroreflex sensitivity and the blood pressure
More informationCauses of Poor BP control Rates
Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationAppendix F: Clinical evidence tables
378 Appendix F: F.1 Blood pressure variability STUDY 1 P. M. Rothwell, S. C. Howard, E. Dolan, E. O'Brien, J. E. Dobson, B. Dahlof, N. R. Poulter, and P. S. Sever. Effects of beta blockers and calciumchannel
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationHypertensive Crises. Controlling high blood pressure prevents disease. Recognition and Management of Acute Hypertensive Emergencies
Controlling high blood pressure prevents disease Recognition and Management of Acute Hypertensive Emergencies David idweiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Functional Genomics
More informationAngina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.
Lonet Tablet Description Lonet contains Atenolol, a synthetic β1 selective (cardioselective) adrenoreceptor blocking agent without membrane stabilising or intrinsic sympathomimetic (partial agonist) activity.
More informationSummary of recommendations
Summary of recommendations Measuring blood pressure (BP) Use the recommended technique at every BP reading to ensure accurate measurements and avoid common errs. Pay particular attention to the following:
More informationData Alert #2... Bi o l o g y Work i n g Gro u p. Subject: HOPE: New validation for the importance of tissue ACE inhibition
Vascular Bi o l o g y Work i n g Gro u p c/o Medical Education Consultants, In c. 25 Sy l van Road South, We s t p o rt, CT 06880 Chairman: Carl J. Pepine, MD Professor and Chief Division of Cardiovascular
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationHypertensives Emergency and Urgency
Hypertensives Emergency and Urgency Budi Yuli Setianto Cardiology Divisision Department of Internal Medicine Faculty of Medicine UGM Sardjito Hospital Yogyakarta Background USA: Hypertension is 30% of
More informationArterial Age and Shift Work
340 Arterial Age and Shift Work Ioana Mozos 1*, Liliana Filimon 2 1 Department of Functional Sciences, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania 2 Department of Occupational
More informationLab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide
Lab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide Main Idea: The function of the circulatory system is to maintain adequate blood flow to all tissues. Clinical
More informationChapter (9) Calcium Antagonists
Chapter (9) Calcium Antagonists (CALCIUM CHANNEL BLOCKERS) Classification Mechanism of Anti-ischemic Actions Indications Drug Interaction with Verapamil Contraindications Adverse Effects Treatment of Drug
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationSYNOPSIS. Publications No publications at the time of writing this report.
Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release
More informationSTATE OF THE ART BP ASSESSMENT
STATE OF THE ART BP ASSESSMENT PROFESSOR MOLECULAR PHARMACOLOGY CONWAY INSTITUE UNIVERSITY COLLEGE DUBLIN CO-CHAIRMAN BLOOD PRESCSURE MANAGEMENT IN LOW RESOURCE SETTINGS CENTRE FOR INTERNATIONAL HUMANITARIAN
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationSECONDARY HYPERTENSION
HYPERTENSION Hypertension is the clinical term used to describe a high blood pressure of 140/90 mmhg or higher (National Institute of Health 1997). It is such a health risk the World Health Organisation
More informationA fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension: Results of a noninvestigational
Hostalek U et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 11 RESEARCH ARTICLE A fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension:
More informationExecutive Summary. Different antihypertensive drugs as first line therapy in patients with essential hypertension 1
IQWiG Reports Commission No. A05-09 Different antihypertensive drugs as first line therapy in patients with essential hypertension 1 Executive Summary 1 Translation of the executive summary of the final
More informationThe incidence of transient myocardial ischemia,
AJH 1999;12:50S 55S Heart Rate and the Rate-Pressure Product as Determinants of Cardiovascular Risk in Patients With Hypertension William B. White Inability to supply oxygen to the myocardium when demand
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More information9/17/2015. Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14.
0 1 2 Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14. 3 Slide notes: Large trials such as ALLHAT, LIFE and ASCOT show that the majority of patients with hypertension will require multiple
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationEvaluation of the Cockroft Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients
Original article Annals of Oncology 15: 291 295, 2004 DOI: 10.1093/annonc/mdh079 Evaluation of the Cockroft Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients G.
More informationdrugs, a middle-aged population of Renfrew and Paisley, towns close to Glasgow [5], and the general population of the West of Scotland [6].
Original article 0 0 0 0 0 Cancer risk of hypertensive patients taking calcium antagonists David J. Hole a, Charles R. Gillis a, Iain R. McCallum b, Gordon T. McInnes c, Pauline L. MacKinnon a, Peter A.
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationFAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION
Br. J. clin. Pharmac. (1982), 14, 187S-19lS BENEFICIAL EFFECTS OF CAPTOPRIL IN LEFT VENTRICULAR FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION J.P. BOUNHOURE, J.G. KAYANAKIS, J.M. FAUVEL & J. PUEL Departments
More information